As we emerge from the COVID-19 pandemic, healthcare has transformed through greater partnerships and collaborations between the healthcare providers. Realigning health priorities at the policy level to enhance the healthcare system is instrumental in improving the health of a nation, a company and an individual. Join us for an insightful session on "Making Health a Priority" as our guest speaker shares his views on what actions need to be taken, from the perspectives of country, company and personal level.
Jonathan L. Pan
Vice President & General Manager, Malaysia
GSK Pharmaceutical Sdn Bhd
Dr Jonathan Pan is currently Vice President and General Manager of Malaysia and Brunei for GlaxoSmithKline Pharmaceutical (GSK).
Previously Jonathan was the VP, Medicine Commercialization Leader - Hematology and a member of the global Oncology Therapy Area leadership team. In this role, Jonathan successfully led a cross-functional team through numerous milestones in preparation for GSK's first Oncology medicine approval since 2013 with the launch of BLENREP. Prior to GSK, Jonathan had various senior commercial, marketing and R&D roles at Aevi Genomic Medicine, BMS, J&J and GSK.
Before joining the pharmaceutical industry, Jonathan also helped to establish the pharmaceutical practice at Scientia Advisors (now Precision Advisors), a boutique consulting firm in Boston. In addition, Jonathan was a senior consultant on IMS Consulting Groups' (now IQVIA) Product and Portfolio Strategy team as well as a consultant on Deloitte's Consulting Enterprise Risk Strategy team, servicing federal clients such as the Nuclear Regulatory Commission, Health and Human Services, and Department of Education. Jonathan also worked with large private equity firms, providing due diligence support on leveraged buy-out options and mezzanine financing.
Jonathan is from the United States of America and is a proud University of Michigan graduate earning his PhD in cellular and molecular biology and an MBA in management.